格隆汇1月29日丨瑞普生物(300119.SZ)在投资者互动平台表示，公司目前无尼帕病毒相关的针对性疫 苗、药品，将持续关注相关病毒动态，合理评估研发机会。 ...

南方财经1月29日电，瑞普生物1月29日在互动平台表示，公司目前无尼帕病毒相关的针对性疫苗、药 品，将持续关注相关病毒动态，合理评估研发机会。 ...

Investment Rating - The report maintains a recommendation rating for the animal health industry, indicating an expectation of growth in the sector over the next 3-6 months, surpassing the benchmark index by more than 5% [4][80]. Core Insights - In 2025, the majority of vaccine varieties saw a year-on-year increase in batch approvals, with notable growth in new vaccine products [6][7]. - The Veterinary Product Index (VPI) for animal medicines increased by 7.2% year-on-year, although there was significant differentiation among product categories [51][56]. - The report emphasizes the importance of innovation in driving performance among companies in the sector, highlighting that successful firms exhibit strong product, marketing, and capital operation innovations [68][71]. Summary by Sections Vaccine Batch Approvals - In December 2025, most vaccine products showed year-on-year growth in batch approvals, particularly in swine vaccines, with notable increases in foot-and-mouth disease vaccine (+24.2%) and pseudorabies vaccine (+1.2%) [6][7]. - For the entire year of 2025, swine vaccines such as foot-and-mouth disease, pseudorabies, and swine fever vaccines saw increases of +6.4%, +5.1%, and +11.7% respectively, while some vaccines like blue ear and swine parvovirus vaccines experienced declines of -3.7% and -4.5% [7][8]. Animal Medicine Raw Materials - The VPI index for animal medicines rose by 7.2% year-on-year in 2025, with significant price increases in macrolide products such as tylosin (+29.5%) and tiamulin (+29.8%), while others like florfenicol and amoxicillin saw declines of -5.9% and -21.0% respectively [51][56]. - The report notes that the market for animal medicines is expected to remain weak in the short term due to ongoing pressures in the breeding sector and seasonal factors [56][68]. Investment Recommendations - The report suggests focusing on undervalued companies with improvement potential, particularly those demonstrating innovation in products and operations. Recommended companies include Zhongmu Co., Ltd., Reap Bio, and others [68][71].

Core Viewpoint - The animal health sector experienced a slight decline of 0.2% on January 28, with Yongshun Biological leading the drop, while the overall market indices showed minor gains [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4151.24, up by 0.27% [1]. - The Shenzhen Component Index closed at 14342.9, up by 0.09% [1]. - The animal health sector's performance is summarized in a table showing individual stock movements, with notable gainers including Biological Shares and Jinhai Biological, which rose by 1.51% and 1.49% respectively [1]. Group 2: Stock Performance - Yongshun Biological saw a significant decline of 7.49%, closing at 10.13, with a trading volume of 141,500 shares and a turnover of 145 million yuan [2]. - Other notable decliners included Shoufeng Holdings and Haili Biological, which fell by 2.21% and 2.08% respectively [2]. - The trading volume and turnover for various stocks in the animal health sector are detailed, indicating varied investor interest [2]. Group 3: Capital Flow - The animal health sector experienced a net inflow of 18.02 million yuan from institutional investors, while retail investors saw a net inflow of 9.33 million yuan [2]. - However, there was a net outflow of 27.35 million yuan from speculative funds, indicating a mixed sentiment among different investor types [2]. - A detailed table shows the net capital flow for individual stocks, highlighting significant movements in and out of various companies [3].

Investment Rating - The overall industry rating is "Positive" for the agriculture sector, indicating expected returns above the CSI 300 index by more than 5% in the next six months [7][52]. Core Views - The pig price has rebounded during the peak season, with the national average price at 12.97 CNY/kg, an increase of 0.19 CNY from last week. The average price for 15 kg piglets is 28.03 CNY/kg, up by 2.89 CNY [6][18]. - The livestock industry is experiencing a slowdown in output growth, with a decrease in slaughter rates. The operating rate of large-scale slaughterhouses is 36.48%, down 2.1 percentage points from last week and 24.63 percentage points year-on-year [6][18]. - The industry is transitioning from losses to profitability, although the pace of capacity reduction is slowing. As of December 2025, the number of breeding sows is 39.61 million, a decrease of 2.9% year-on-year [7][19]. - The chicken industry is facing high capacity levels, with prices expected to fluctuate in the medium term. The average price for broiler chickens is 3.7 CNY/kg, down 0.07 CNY from last week [8][21]. - The yellow chicken market is experiencing low capacity levels, with prices expected to rise in the medium term due to tight supply and seasonal demand [22][21]. Summary by Sections Livestock Industry - The pig price has rebounded, but the increase is narrowing. The average price is 12.97 CNY/kg, with a slight increase in piglet prices [6][18]. - The operating rate of slaughterhouses has decreased, indicating a slowdown in the output growth of listed companies [6][18]. - The industry is moving towards profitability, but the capacity reduction is slowing down, with breeding sow numbers at 39.61 million [7][19]. Poultry Industry - The chicken industry is at a high capacity level, with prices expected to remain stable in the medium term. The average price for broiler chickens is 3.7 CNY/kg [8][21]. - The yellow chicken market is experiencing low capacity, with prices expected to rise due to seasonal demand [22][21]. Crop Industry - Grain prices are on the rise, with corn at 2376 CNY/ton and wheat at 2525 CNY/ton, indicating a positive outlook for the planting sector [11][24]. - The seed industry is benefiting from favorable policies and technological advancements, with long-term investment value highlighted [10][23]. Recommended Companies - The report recommends buying shares in Zhongchong Co., Muyuan Foods, and Suqian Agricultural Development, all rated as "Buy" [4].

Market Overview - The animal health sector experienced a decline of 2.78% on January 27, with Huisheng Biological leading the drop [1] - The Shanghai Composite Index closed at 4139.9, up 0.18%, while the Shenzhen Component Index closed at 14329.91, up 0.09% [1] Stock Performance - Key stocks in the animal health sector showed varied performance, with the following notable changes: - Huisheng Biological (300871) closed at 29.89, down 8.37% with a trading volume of 376,900 shares and a transaction value of 1.148 billion [2] - Other significant declines included: - ST Lvkang (002868) down 3.86% to 35.40 [1] - Kexin Biological (688526) down 3.88% to 17.10 [1] - Haili Biological (603718) down 4.13% to 6.73 [1] Capital Flow - The animal health sector saw a net outflow of 45.7033 million from institutional investors, while retail investors experienced a net outflow of 59.3359 million [2] - Conversely, speculative funds recorded a net inflow of 105 million [2] Individual Stock Capital Flow - Notable capital flow for specific stocks included: - ST Lvkang (002868) had a net inflow of 29.8876 million from institutional investors, but a net outflow of 40.6641 million from speculative funds [3] - Zhongmu Co. (600195) saw a net inflow of 21.2767 million from institutional investors, with a significant net outflow of 66.5383 million from retail investors [3] - Jinhe Biological (002688) had a net inflow of 19.2937 million from institutional investors, but also faced a net outflow from retail investors [3]

Group 1 - The animal health sector experienced a significant increase of 5.61% on January 26, with Yongshun Biological leading the gains [1] - The Shanghai Composite Index closed at 4132.61, down 0.09%, while the Shenzhen Component Index closed at 14316.64, down 0.85% [1] - Key stocks in the animal health sector showed notable price increases, with Yongshun Biological rising by 27.18% to a closing price of 11.79, and Huisheng Biological increasing by 20.01% to 32.62 [1] Group 2 - The animal health sector saw a net inflow of 437 million yuan from institutional investors, while retail investors experienced a net outflow of 307 million yuan [2] - The trading volume for Yongshun Biological reached 292,600 shares, contributing to a total transaction value of 328 million yuan [1][2] - The stock performance of various companies in the sector varied, with some experiencing significant gains while others faced declines in retail investment [3]

Group 1 - The core viewpoint of the news is that Reap Bio has seen a 5% increase in stock price, reaching 21.40 CNY per share, with a trading volume of 221 million CNY and a turnover rate of 3.17%, resulting in a total market capitalization of 9.946 billion CNY [1] - Reap Bio, established on August 2, 2001, and listed on September 17, 2010, is located in the Tianjin Free Trade Zone and specializes in the research, production, sales, and technical services of veterinary biological products, chemical drugs, biological agents, and other related products [1] - The main business revenue composition of Reap Bio is 77.95% from animal protection business and 22.05% from the pet supply chain [1] Group 2 - From the perspective of the top ten circulating shareholders, Guotai Fund's ETF, Guotai Zhongzheng Animal Husbandry ETF (159865), increased its holdings by 2.3571 million shares, totaling 6.3383 million shares, which accounts for 1.89% of the circulating shares [2] - The Guotai Zhongzheng Animal Husbandry ETF has a current scale of 5.949 billion CNY, with a year-to-date loss of 0.41% and a one-year return of 15.98% [2] - The fund manager of Guotai Zhongzheng Animal Husbandry ETF, Liang Xing, has a tenure of 9 years and 235 days, with the fund's total asset size at 29.35 billion CNY and a best return of 1112.34% during the tenure [3]

Market Overview - The animal health sector experienced a decline of 0.32% on January 23, with BioShares leading the drop [1] - The Shanghai Composite Index closed at 4136.16, up 0.33%, while the Shenzhen Component Index closed at 14439.66, up 0.79% [1] Stock Performance - Notable gainers in the animal health sector included: - Qudongli (920275) with a closing price of 9.68, up 4.09% on a trading volume of 36,300 shares and a turnover of 34.72 million yuan [1] - Haili Biological (603718) closed at 6.55, up 1.24% with a trading volume of 95,100 shares and a turnover of 61.91 million yuan [1] - Deyu Biological (920970) closed at 8.44, up 1.20% with a trading volume of 19,200 shares and a turnover of 16.26 million yuan [1] - Conversely, BioShares (600201) closed at 17.35, down 1.42% with a trading volume of 315,700 shares and a turnover of 551 million yuan [2] Capital Flow - The animal health sector saw a net outflow of 142 million yuan from institutional investors, while retail investors experienced a net inflow of 124 million yuan [2][3] - Specific stock capital flows included: - Zhongmu Shares (600195) with a net inflow of 14.27 million yuan from institutional investors [3] - Qudongli (920275) had a net inflow of 2.44 million yuan from retail investors [3] - Deyu Biological (920970) faced a net outflow of 1.04 million yuan from institutional investors [3]

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 作为国内兽用生物制品领域的重要企业，天康制药股份有限公司（以下简称"天康制药"）冲击北交所 IPO的进程，其在问询中暴露的一系列问题引发市场与监管的普遍关注。 1月13日，公司披露的回复文件虽力图对监管连环追问做出详尽说明，但其呈现的数据与解释，非但未 能完全驱散市场疑虑，业绩下滑、客户流失、应收账款高企及募投项目合理性等问题仍悬而未决。 行业复苏公司业绩不增反降 大额非经常损益或有利润调节可能 监管层首要且反复质询的，是天康制药报告期内业绩的持续下滑，尤其是与行业整体趋势的明显背离。 财务数据显示，2022年至2024年，公司归母净利润已从2.04亿元滑落至1.53亿元，扣非净利润近两年同 比下滑幅度分别为18.36%和11.20%，疲态尽显。 进入2025年，公司业绩颓势加剧，前三季度营业收入6.82亿元，同比下降20.49%；净利润1.06亿元，同 比暴跌42.44%。同期同行业可比公司如瑞普生物、科前生物、普莱柯等，营业收入平均增长1.60%，净 利润平均增长49.06%。 值得关注的是，本就显露颓势的业绩还或存在利润调节的现象 ...